Vanguard Group Inc Delcath Systems, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,394,028 shares of DCTH stock, worth $22.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,394,028
Previous 1,224,768
13.82%
Holding current value
$22.4 Million
Previous $14.4 Million
23.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding DCTH
# of Institutions
104Shares Held
12.1MCall Options Held
79KPut Options Held
53.3K-
Deerfield Management Company, L.P. (Series C) New York, NY813KShares$13.1 Million0.26% of portfolio
-
Vivo Capital, LLC Palo Alto, CA750KShares$12.1 Million2.59% of portfolio
-
Exodus Point Capital Management, LP New York, NY699KShares$11.2 Million0.09% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA557KShares$8.96 Million0.0% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY539KShares$8.66 Million0.1% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $138M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...